论文部分内容阅读
By one case of hemangioendothelioma of bone accompanying pulmonary metastasis was treated with rh-endostatin injection (Endostar) combined with chemotherapy. The patient got partial response (PR) for 3 years after the application of Endostar maintenance therapy and Endostar combined with taxane-based chemotherapy. During the period of using Endostar as monotherapy, the patient got long-term disease control and good quality of life. There was no drug related adverse event during the therapy of Endostar. Suggested continued using of Endostar combined with chemotherapy could achieve an convinced therapeutic effect. Then using Endostar as maintenance treatment after patient got the optimal efficacy was feasible and profitable. This treatment strategy of long-term administration of Endostar was worthy of further observation, to explore the feasibility for long-term administration of combined with chemotherapy in the treatment of hemangioendothelioma of bone accompanying pulmonary metastasis.
The one patient got partial response (PR) for 3 years after the application of Endostar maintenance therapy and Endostar combined with taxane-based chemotherapy During the period of using Endostar as monotherapy, the patient got long-term disease control and good quality of life. There was no drug related adverse event during the therapy of Endostar. effect. Then using Endostar as maintenance treatment after patient got the optimal efficacy was feasible and profitable. This treatment strategy of long-term administration of Endostar was worthy of further observation, to explore the feasibility for long-term administration of combined with chemotherapy in the treatment of hemangioendothelioma of bone accompanying pulmonary metastasis .